DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the presentation of positive interim data from its ongoing Phase 1/2 clinical trial of IDCT (rebonuputemcel), an allogeneic injectable discogenic cell therapy for degenerative disc disease…
eTurboNews gli articoli sono riservati agli abbonati. L'abbonamento è GRATIS.
Gli abbonati accedono qui Clicca qui per iscriverti GRATUITAMENTE
Gli abbonati accedono qui Clicca qui per iscriverti GRATUITAMENTE
COSA TOGLIERE DA QUESTO ARTICOLO:
- , a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the presentation of positive interim data from its ongoing Phase 1/2 clinical trial of IDCT (rebonuputemcel), an allogeneic injectable discogenic cell therapy for degenerative disc disease….
- L'abbonamento è GRATUITO.
- eTurboNews gli articoli sono riservati agli abbonati.
